Health · Mental Health · 6 hrs ago
Research explores blood markers, mindfulness and fitness in depression care
Researchers are presenting new findings on alternative approaches to depression at Neuroscience 2026, an annual brain science meeting.
One study found blood plasma markers that may predict response to psilocybin and ketamine therapies for an individual’s depression.
Another found that adolescents who completed an online mind-body program and had decreases in gray matter in the cingulate cortex also showed lower depression symptom scores.
A study of older adults without cognitive impairment found thinner tissue in a brain region among those with depression, and suggested higher body mass index may partly explain the difference.
Together, the findings examine how treatment response and brain differences vary, rather than suggesting one approach works for everyone.
The research is part of efforts to develop more precise treatments for depression, a leading cause of disability worldwide.
Researchers reported blood plasma markers that may predict whether psilocybin and ketamine therapies will work for an individual with depression.
The findings are among research to be presented at Neuroscience 2026, the Society for Neuroscience’s annual meeting.
A study of adolescents linked changes in cingulate cortex gray matter after an online mind-body intervention with reduced depressive symptoms.
A separate study found thinner brain tissue in a region of cognitively unimpaired older adults with depression, potentially partly related to higher body mass index.
The research aims to advance precision treatments for depression.
- Who
- Researchers including Tracy L. Bale, Roma Kidambi and Meredith Braskie.
- What
- Studies examined blood markers that may predict treatment response, mindfulness-related brain changes and brain tissue thickness in depression.
- When
- The findings are to be presented at Neuroscience 2026.
- Where
- Neuroscience 2026, the Society for Neuroscience’s annual meeting. The meeting location is not stated.
- Why
- The research explores approaches to treating depression and advancing precision treatments.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Blood markers
- May predict individual response to psilocybin and ketamine therapies
- Adolescent study
- Cingulate cortex gray matter decreases were associated with lower depressive symptom scores
- Older adults
- Thinner brain tissue was observed in cognitively unimpaired adults with depression
- Conference
- Neuroscience 2026
What people are saying
The research presented at Neuroscience 2026 makes important strides towards the goal of precision treatments for depression